Biogen rises after FDA clears at-home use of Alzheimer's drug
BUZZ-Biogen rises after FDA clears at-home use of Alzheimer's drug ** Shares of drugmaker Biogen BIIB.O rise 5.3% to $209.69
** FDA approves a starting dose regimen for the under-the-skin injection of Eisai and Biogen's Alzheimer's drug Leqembi, allowing patients to begin treatment at home
** Previously, Leqembi was approved only with an intravenous starting dosage before patients could transition to other dosing options
** Leqembi is approved for early Alzheimer's disease, a memory-robbing brain disorder affecting more than 6.5 million Americans
** FDA says data showed the injection achieved drug exposure comparable to the intravenous regimen, supporting similar efficacy and safety
** FDA recommends genetic testing before treatment because certain patients face a higher risk of side effects
** Including session's moves, stock up ~18% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova